2025 United Kingdom Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 United Kingdom Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United Kingdom's anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc.. GSK, a UK-based leader, holds a 20-25% market share with a broad vaccine portfolio, including recent launches like Arexvy for RSV and Shingrix for herpes zoster. Sanofi focuses on infectious disease vaccines with strong R&D, particularly in meningococcal vaccines. Merck provides broad-spectrum vaccines such as Capvaxive pneumococcal vaccine, and Pfizer dominates the pneumococcal segment with Prevnar 20, leveraging extensive global distribution.
In addition, AstraZeneca, also headquartered in the UK, contributes notably in infectious disease vaccines, exemplified by its collaboration on the Oxford-AstraZeneca COVID-19 vaccine, approved in the UK in late 2020. AstraZeneca combines its pharmaceutical and biotech strengths with research centers in Cambridge and beyond. Emerging players like Moderna, with mRNA vaccine technology, also have influence in the UK market through innovative pipeline offerings targeting respiratory illnesses and other infections. These companies, driven by government immunization initiatives and strong R&D, remain central to vaccine development and anti-infective disease control in the United Kingdom.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United Kingdom's anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc.. GSK, a UK-based leader, holds a 20-25% market share with a broad vaccine portfolio, including recent launches like Arexvy for RSV and Shingrix for herpes zoster. Sanofi focuses on infectious disease vaccines with strong R&D, particularly in meningococcal vaccines. Merck provides broad-spectrum vaccines such as Capvaxive pneumococcal vaccine, and Pfizer dominates the pneumococcal segment with Prevnar 20, leveraging extensive global distribution.
In addition, AstraZeneca, also headquartered in the UK, contributes notably in infectious disease vaccines, exemplified by its collaboration on the Oxford-AstraZeneca COVID-19 vaccine, approved in the UK in late 2020. AstraZeneca combines its pharmaceutical and biotech strengths with research centers in Cambridge and beyond. Emerging players like Moderna, with mRNA vaccine technology, also have influence in the UK market through innovative pipeline offerings targeting respiratory illnesses and other infections. These companies, driven by government immunization initiatives and strong R&D, remain central to vaccine development and anti-infective disease control in the United Kingdom.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
